Polypharmacology News and Research

RSS
Moffitt Cancer Center researchers identify hidden target of ROS1 inhibitor lorlatinib

Moffitt Cancer Center researchers identify hidden target of ROS1 inhibitor lorlatinib

Research shows how a very low dose of rhenium metal complex kills ovarian cancer cells

Research shows how a very low dose of rhenium metal complex kills ovarian cancer cells

Researchers analyze potential of niclosamide as a SARS-CoV-2 treatment

Researchers analyze potential of niclosamide as a SARS-CoV-2 treatment

MD Anderson receives nearly $13 million from CPRIT to support research efforts

MD Anderson receives nearly $13 million from CPRIT to support research efforts

FDA approved drug found to have anti-cancer activity against previously unknown targets

FDA approved drug found to have anti-cancer activity against previously unknown targets

New on-line resource allows user to virtually test effectiveness, specificity of potential drug

New on-line resource allows user to virtually test effectiveness, specificity of potential drug

New approach to drug design may yield more effective and less toxic cancer medicines

New approach to drug design may yield more effective and less toxic cancer medicines

Scientists create cancer model built in the fruit fly Drosophila

Scientists create cancer model built in the fruit fly Drosophila

Determining success or failure in cholesterol-controlling drugs

Determining success or failure in cholesterol-controlling drugs

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.